NIAID. In March, 2005, XOMA was awarded a $15 million contract from National Institute of Allergy and Infectious Diseases (NIAID) to produce three anti-botulinum neurotoxin monoclonal antibodies designed to protect U.S. citizens against the harmful effects of biological agents used in bioterrorism.  On July 28^th 2006, XOMA was awarded an additional $16 million follow-on contract to create and produce an innovative injectable product comprised of the three anti-type A-botulinum neurotoxin monoclonal antibodies to support entry into Phase I human safety clinical trials.

News Releases:

(September 28, 2006) XOMA and AVEO announced a $6 million agreement under which XOMA manufactures and supplies AV-299, AVEO's novel anti-HGF antibody for cancer.  Under the agreement XOMA will create AV-299 production cell lines, and will conduct process and assay development, as well as cGMP manufacturing activities in support of AVEO's IND filing and early clinical trials.  This agreement follows the successful completion of the Human Engineering^TM (HE^TM) of AV-299.  HE^TM technology is a patented, clinically tested humanization technology for modifying non-human antibodies to make them suitable for medical purposes in humans.  This 93%-95% human antibody is generated in approximately 3 months with preserved antigen binding, structure, and function has allowed AVEO to accelerate product development timelines for their AV-299 program.

(July 31, 2006) XOMA Awarded New $16 Million BioDefense Contract with NIAID; Contracts Now Total $31 Million for XOMA to Produce Anti-Botulism Antibodies to Support Human Clinical Trials

(March 10. 2005) XOMA Awarded $15 Million Contract from NIAID to Help Fight Bioterrorism